Table A1.
Parkinson’s disease patients firstly treated with DBS, CLI as second treatment—single center.
| Case | Sex | Age at PD Diagnosis (Years) | Age at Initiation Initial Treatment (Years) | Interval between Treatments (Months) | Pre-DBS UPDRS-III Off/On Medication § | LEDD Pre-First/Pre-Second/Post-Second Treatment | Neuro-Surgery Prior to DBS | DBS Target | Initial Effect of First Treatment | Indication(s) for Second Treatment | Effect of Second Treatment CLI | DBS Treatment Continued | Adverse Effects of Both Treatments | Patient Satisfied after 2nd Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | F | 33 | 42 | 43 | 45/4 | 600/500/737 | R/L STN | Good | MF | No change | Yes | DBS: apathy | Yes | |
| B | M | 43 | 50 | 60 | 52/39 | 300/1520/1965 | R pallidotomy | R/L STN | Good | MFD | No change | Yes | DBS: pain at implant site, lead infection | Yes |
| C | F | 45 | 50 | 45 | 45/10 | 2050/1545/2628 | R/L GPi | Poor | MFD, GI | Some improvement | Yes | DBS: dystonia, cognitive decline | Yes | |
| D | F | 45 | 55 | 41 | UA/UA | 715/1650/3164 | R/L STN | Good | MFD, GI | No change | Yes | DBS: right STN lead repositioned to GPi | UA | |
| E | M | 43 | 65 | 83 | 70 */17 * | 500/500/2708 | R thalamotomy | R/L STN | Good | MF, BI, DBS complications | Large improvement | Unilateral | DBS: SI, BI, lead infection | Yes |
| F | F | 36 | 45 | 60 | 34 */32 * | 1350/1150/1510 | F pallidotomy | R/L STN | Good | MF | Large improvement | Yes | None reported | Yes |
| G | F | 46 | 65 | 88 | 78/35 | 350/950/375 | R pallidotomy | R/L STN | Little | MF, GI | Some improvement | Yes, CLI stopped | DBS: BI CLI: pain, site infected |
No |
| H | M | 43 | 52 | UA | UA/UA | UA/UA/UA | R/L STN | UA | UA | UA | UA | UA | Yes | |
| I | M | 52 | 57 | 34 | 39 */12 * | UA/1500/UA | R/L STN | Little | MF, GI | Large improvement | Yes | DBS: BI, SI | Yes | |
| Mean/Total | Mean 43 | Mean 53 | Mean 57 |
838/1164/1870
(n = 7/n = 8/n = 7) |
5 improved, 3 no change, 1 UA | 7 satisfied, 1 unsatisfied, 1 UA | ||||||||
BI: balance impairment; CLI: continuous levodopa/carbidopa infusion; DBS: deep brain stimulation; F: female; GI: gait impairment; GPi: globus pallidus interna; LEDD: levodopa equivalent daily dose; M: male; MF: motor fluctuations; MFD: motor fluctuations and dyskinesias; PD: Parkinson’s disease; R/L: right/left; SI: speech impairment; STN: subthalamic nucleus; UA: unavailable; UPDRS: Unified Parkinson’s Disease Rating Scale; part III (*: MDS-UPDRS-III (post 2013) was used). § Pre and post CLI UPDRS-III were not available for direct comparison.